OncoCyte (NASDAQ:OCX) Receives “Buy” Rating from Needham & Company LLC

Needham & Company LLC restated their buy rating on shares of OncoCyte (NASDAQ:OCX) in a research note published on Tuesday, Benzinga reports. They currently have a $4.25 price objective on the stock.

Separately, StockNews.com initiated coverage on shares of OncoCyte in a research note on Tuesday. They set a sell rating on the stock. One analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat.com, OncoCyte currently has a consensus rating of Hold and a consensus price target of $4.06.

OncoCyte Price Performance

NASDAQ:OCX opened at $3.12 on Tuesday. OncoCyte has a one year low of $2.08 and a one year high of $4.34. The company’s 50-day simple moving average is $3.07 and its 200 day simple moving average is $2.93.

OncoCyte (NASDAQ:OCX) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.36) EPS for the quarter. OncoCyte had a negative return on equity of 149.88% and a negative net margin of 3,558.46%. The business had revenue of $0.10 million for the quarter.

Insider Transactions at OncoCyte

In other news, major shareholder Broadwood Partners, L.P. bought 1,315,339 shares of the company’s stock in a transaction dated Wednesday, October 2nd. The shares were purchased at an average price of $2.95 per share, for a total transaction of $3,880,250.05. Following the completion of the purchase, the insider now owns 6,244,405 shares in the company, valued at approximately $18,420,994.75. This represents a 0.00 % increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In related news, major shareholder Broadwood Partners, L.P. acquired 1,315,339 shares of the firm’s stock in a transaction dated Wednesday, October 2nd. The stock was purchased at an average cost of $2.95 per share, with a total value of $3,880,250.05. Following the completion of the acquisition, the insider now directly owns 6,244,405 shares of the company’s stock, valued at approximately $18,420,994.75. This trade represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Andrea S. James acquired 33,670 shares of the firm’s stock in a transaction dated Wednesday, October 2nd. The shares were bought at an average cost of $2.97 per share, with a total value of $99,999.90. Following the completion of the acquisition, the chief financial officer now directly owns 33,670 shares of the company’s stock, valued at $99,999.90. The disclosure for this purchase can be found here. Insiders own 1.94% of the company’s stock.

About OncoCyte

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.